Monzo Acquires UK Mortgage Broker in Landmark Deal

ago 7 hours
Monzo Acquires UK Mortgage Broker in Landmark Deal

Monzo has recently made a significant acquisition by purchasing the UK-based digital mortgage broker, Habito. This move marks Monzo’s first major acquisition as it aims to enhance its “all-in-one” superapp offerings. The announcement was made on a Friday in December 2025, following Monzo’s achievement of reaching 14 million customers.

Details of the Acquisition

While the financial details of the deal remain undisclosed, it’s known that Habito had approximately £1.3 million in cash as of December 2024. This acquisition is part of Monzo’s strategy to strengthen its position in the mortgage market.

Statements from Executives

  • Kunal Malani, Monzo’s Chief Banking Officer, characterized the acquisition as a “huge step” towards ensuring money works effectively for everyone.
  • Ying Tan, CEO of Habito, expressed pride in the company’s achievements and enthusiasm for the future collaboration with Monzo, aiming to transform the mortgage experience for customers.

Monzo’s Growth and Strategy

Over the past year, Monzo has intensified its focus on the mortgage sector. Recent research indicated that UK homeowners possess around £5.3 billion they wish to allocate towards mortgage over-payments annually. However, many lack the necessary tools or knowledge for this. Implementing solutions could potentially save homeowners up to £2.3 billion in mortgage interest each year.

Competitive Landscape

This acquisition also represents a strategic move for Monzo as it vies to compete with Revolut, a prominent player in the super-app space. Revolut has expanded its services significantly, incorporating lifestyle features such as hotel bookings, mobile plans, and cryptocurrency services.

Leadership Changes at Monzo

In a related development, Monzo’s leadership has experienced a change. TS Anil, who served as CEO for five years, departed from the role in October 2025. He will be succeeded by Diana Layfield, who is also a board member at AstraZeneca. Anil’s departure was reportedly influenced by disagreements with the board concerning the company’s public listing strategy, with varying views on prioritizing the UK market versus ambitions in the U.S.